GURUFOCUS.COM » STOCK LIST » Asia » Hong Kong » HKSE » InnoCare Pharma Ltd (HKSE:09969) » Definitions » Other Current Liabilities
Switch to:

InnoCare Pharma (HKSE:09969) Other Current Liabilities

: HK$51 Mil (As of Jun. 2022)
View and export this data going back to 2020. Start your Free Trial

InnoCare Pharma's other current liabilities for the quarter that ended in Jun. 2022 was HK$51 Mil.

InnoCare Pharma's quarterly other current liabilities increased from Jun. 2021 (HK$22 Mil) to Dec. 2021 (HK$52 Mil) but then declined from Dec. 2021 (HK$52 Mil) to Jun. 2022 (HK$51 Mil).

InnoCare Pharma's annual other current liabilities increased from Dec. 2019 (HK$17 Mil) to Dec. 2020 (HK$36 Mil) and increased from Dec. 2020 (HK$36 Mil) to Dec. 2021 (HK$52 Mil).


InnoCare Pharma Other Current Liabilities Historical Data

The historical data trend for InnoCare Pharma's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InnoCare Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21
Other Current Liabilities
- - - - -

InnoCare Pharma Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22
Other Current Liabilities Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

InnoCare Pharma Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.


InnoCare Pharma Other Current Liabilities Related Terms

Thank you for viewing the detailed overview of InnoCare Pharma's Other Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


InnoCare Pharma (HKSE:09969) Business Description

InnoCare Pharma logo
Traded in Other Exchanges
Address
No. 8 Life Science Park Road, Building 8, Zhongguancun Life Science Park, Changping District, Beijing, CHN, 100084
InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. Its commercial drug candidate is Orelabrutinib and clinical-stage drug candidates are ICP-192, ICP-105, ICP-723, and others.

InnoCare Pharma (HKSE:09969) Headlines

No Headlines